吉西他滨对膀胱癌细胞中卡铂-DNA 单加合物的形成和修复的调节作用很小。
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.
机构信息
Division of Hematology & Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, California 95817, USA.
出版信息
Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. doi: 10.1021/tx1003547. Epub 2010 Oct 28.
Abstract
We are developing a method to identify cellular resistance to carboplatin by using accelerator mass spectrometry to measure carboplatin-DNA adducts formed from drug microdoses (∼1/100th the therapeutic dose). Such an approach would be particularly useful if it is still valid in combination chemotherapy. We examined whether the addition of gemcitabine, another chemotherapeutic drug, could influence carboplatin-DNA adduct levels. There were no substantial differences in the levels of carboplatin-DNA adducts in cells upon exposure to the carboplatin/gemcitabine combination at various doses and schedules. These data demonstrate that microdosing is feasible for the characterization of carboplatin resistance when given in combination with gemcitabine.
摘要
我们正在开发一种方法，通过使用加速器质谱法来测量由药物微剂量（约为治疗剂量的 1/100）形成的卡铂-DNA 加合物，从而鉴定细胞对卡铂的耐药性。如果这种方法在联合化疗中仍然有效，那么它将特别有用。我们研究了另一种化疗药物吉西他滨的加入是否会影响卡铂-DNA 加合物的水平。在不同剂量和方案下，细胞暴露于卡铂/吉西他滨联合用药时，卡铂-DNA 加合物的水平没有明显差异。这些数据表明，微剂量在与吉西他滨联合使用时，可用于鉴定卡铂耐药性。
相似文献
1
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.吉西他滨对膀胱癌细胞中卡铂-DNA 单加合物的形成和修复的调节作用很小。
Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. doi: 10.1021/tx1003547. Epub 2010 Oct 28.
2
A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.一种用于表征卡铂-DNA 单加合物的形成和修复以及化学抗性的微剂量方法。
Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.
3
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.通过膀胱癌细胞培养模型中的功能和基因表达分析对诱导性铂耐药进行分子剖析
PLoS One. 2016 Jan 22;11(1):e0146256. doi: 10.1371/journal.pone.0146256. eCollection 2016.
4
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.微剂量诱导的药物-DNA加合物作为人类和小鼠化疗耐药性的生物标志物
Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.
5
Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity.紫杉醇增强卡铂与DNA加合物的形成及细胞毒性。
Chem Res Toxicol. 2015 Dec 21;28(12):2250-2. doi: 10.1021/acs.chemrestox.5b00422. Epub 2015 Nov 11.
6
Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.卡铂和吉西他滨联合的细胞毒性活性分析。
Anticancer Res. 2010 Nov;30(11):4573-8.
7
Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.通过加速器质谱法测定卡铂与基因组DNA及膀胱癌细胞中DNA结合的动力学。
Chem Res Toxicol. 2006 May;19(5):622-6. doi: 10.1021/tx060058c.
8
Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.晚期癌症患者每两周一次吉西他滨与卡铂剂量递增研究。
Am J Clin Oncol. 2007 Oct;30(5):481-6. doi: 10.1097/COC.0b013e31804b45c3.
9
Gemcitabine in bladder cancer.吉西他滨用于膀胱癌治疗
Expert Opin Pharmacother. 2007 Dec;8(18):3251-6. doi: 10.1517/14656566.8.18.3251.
10
A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.一种用于研究非小细胞肺癌铂敏感性的诊断性微剂量给药方法。
Int J Cancer. 2017 Aug 1;141(3):604-613. doi: 10.1002/ijc.30747. Epub 2017 May 15.
引用本文的文献
1
Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin and .基于前药的纳米递药策略提高卡铂和 的抗肿瘤能力。
Drug Deliv. 2021 Dec;28(1):1272-1280. doi: 10.1080/10717544.2021.1938754.
2
Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science.毒理学与医学中的放射性碳示踪剂：技术与科学的最新进展
Toxics. 2019 May 9;7(2):27. doi: 10.3390/toxics7020027.
3
Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.铂类药物细胞毒性与乳腺癌细胞系panel 中药物-DNA 加合物水平的相关性。
Chem Res Toxicol. 2018 Dec 17;31(12):1293-1304. doi: 10.1021/acs.chemrestox.8b00170. Epub 2018 Nov 19.
4
Anti-cancer characteristics and ototoxicity of platinum(II) amine complexes with only one leaving ligand.仅有一种离去配体的铂（II）胺配合物的抗癌特性和耳毒性。
PLoS One. 2018 Mar 7;13(3):e0192505. doi: 10.1371/journal.pone.0192505. eCollection 2018.
5
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.来自抗癌药物的DNA加合物作为精准医学的候选预测标志物。
Chem Res Toxicol. 2017 Jan 17;30(1):388-409. doi: 10.1021/acs.chemrestox.6b00380. Epub 2017 Jan 3.
6
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.微剂量诱导的药物-DNA加合物作为人类和小鼠化疗耐药性的生物标志物
Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.
7
Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.加速器质谱在人类健康与分子毒理学中的应用。
Chem Res Toxicol. 2016 Dec 19;29(12):1976-1986. doi: 10.1021/acs.chemrestox.6b00234. Epub 2016 Oct 11.
8
Diagnostic Microdosing Approach to Study Gemcitabine Resistance.研究吉西他滨耐药性的诊断性微剂量给药方法。
Chem Res Toxicol. 2016 Nov 21;29(11):1843-1848. doi: 10.1021/acs.chemrestox.6b00247. Epub 2016 Oct 10.
9
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.用于肺癌和膀胱癌靶向及铂类化疗的个性化医疗。
Bioanalysis. 2013 Feb;5(3):369-91. doi: 10.4155/bio.12.325.
10
Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.算法模型定量评估了代谢抑制对吉西他滨疗效的互补贡献。
PLoS One. 2012;7(12):e50176. doi: 10.1371/journal.pone.0050176. Epub 2012 Dec 11.
本文引用的文献
1
Human microdosing for the prediction of patient response.用于预测患者反应的人体微剂量给药。
Bioanalysis. 2010 Mar;2(3):373-6. doi: 10.4155/bio.10.3.
2
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.接受顺铂同步放化疗患者的顺铂-DNA加合物形成：正常组织与原发肿瘤之间缺乏相关性
Cancer Chemother Pharmacol. 2008 May;61(6):1075-81. doi: 10.1007/s00280-007-0545-1. Epub 2007 Jul 18.
3
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.ATM和ATR底物分析揭示了对DNA损伤作出反应的广泛蛋白质网络。
Science. 2007 May 25;316(5828):1160-6. doi: 10.1126/science.1140321.
4
Mechanisms of resistance to cisplatin and carboplatin.顺铂和卡铂的耐药机制。
Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31. doi: 10.1016/j.critrevonc.2007.02.001. Epub 2007 Mar 1.
5
Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.通过加速器质谱法测定卡铂与基因组DNA及膀胱癌细胞中DNA结合的动力学。
Chem Res Toxicol. 2006 May;19(5):622-6. doi: 10.1021/tx060058c.
6
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.一项关于卡铂联合吉西他滨以标准速率或固定剂量率输注用于晚期非小细胞肺癌患者的多中心随机II期研究。
Ann Oncol. 2006 Jul;17(7):1128-33. doi: 10.1093/annonc/mdl084. Epub 2006 May 2.
7
Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective.多种遗传和表观遗传相互作用机制促成耐药肿瘤的克隆选择：当前观点与新的治疗前景。
J Cell Physiol. 2006 Jun;207(3):571-81. doi: 10.1002/jcp.20515.
8
DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry.用于通过加速器质谱法定量加合物水平的DNA分离和样品制备。
Methods Mol Biol. 2005;291:21-7. doi: 10.1385/1-59259-840-4:021.
9
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.DNA加合物水平作为接受每日顺铂和放疗的非小细胞肺癌患者预后的预测指标。
Int J Cancer. 2000 Mar 20;89(2):160-6.
10
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.ERCC1反义RNA的表达消除了吉西他滨与顺铂在错配修复缺陷但核苷酸切除修复功能正常的人结肠肿瘤细胞中介导的细胞毒性协同作用。
Clin Cancer Res. 2000 Mar;6(3):773-81.
Zotero 插件